These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 21122130)

  • 1. KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice.
    Sundström M; Edlund K; Lindell M; Glimelius B; Birgisson H; Micke P; Botling J
    BMC Cancer; 2010 Dec; 10():660. PubMed ID: 21122130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparability study of 5 commercial KRAS tests.
    Oliner K; Juan T; Suggs S; Wolf M; Sarosi I; Freeman DJ; Gyuris T; Baron W; Bakker A; Parker A; Patterson SD
    Diagn Pathol; 2010 Apr; 5():23. PubMed ID: 20398393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells.
    Lewandowska MA; Jóźwicki W; Żurawski B
    Mol Diagn Ther; 2013 Jun; 17(3):193-203. PubMed ID: 23606169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS gene mutation in a series of unselected colorectal carcinoma patients with prognostic morphological correlations: a pyrosequencing method improved by nested PCR.
    de Macêdo MP; de Melo FM; Lisboa BC; Andrade LD; de Souza Begnami MD; Junior SA; Ribeiro HS; Soares FA; Carraro DM; da Cunha IW
    Exp Mol Pathol; 2015 Jun; 98(3):563-7. PubMed ID: 25835782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach.
    Carotenuto P; Roma C; Rachiglio AM; Tatangelo F; Pinto C; Ciardiello F; Nappi O; Iaffaioli RV; Botti G; Normanno N
    Pharmacogenomics; 2010 Aug; 11(8):1169-79. PubMed ID: 20712532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas.
    Harlé A; Busser B; Rouyer M; Harter V; Genin P; Leroux A; Merlin JL
    Virchows Arch; 2013 Mar; 462(3):329-35. PubMed ID: 23400679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of KRAS mutations in colorectal cancer with Fast COLD-PCR.
    Carotenuto P; Roma C; Cozzolino S; Fenizia F; Rachiglio AM; Tatangelo F; Iannaccone A; Baron L; Botti G; Normanno N
    Int J Oncol; 2012 Feb; 40(2):378-84. PubMed ID: 21971641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma.
    Lee S; Brophy VH; Cao J; Velez M; Hoeppner C; Soviero S; Lawrence HJ
    Virchows Arch; 2012 Feb; 460(2):141-9. PubMed ID: 22173329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation.
    Gao J; Li YY; Sun PN; Shen L
    World J Gastroenterol; 2010 Oct; 16(38):4858-64. PubMed ID: 20939116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories.
    Feigelson HS; Goddard KA; Johnson MA; Funk KC; Rahm AK; Kauffman TL; Chitale DA; Le Marchand L; Richards CS
    BMC Res Notes; 2012 Apr; 5():196. PubMed ID: 22534075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of KRAS new predictive marker in a clinical laboratory.
    Bando I; Cillero L; Sanz-Ortega J; Llovet P; Pescador P; Ferrer M; de la Hoya M; Sastre J; García ED; Caldés T
    Clin Transl Oncol; 2012 Dec; 14(12):937-42. PubMed ID: 22865324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay.
    Chang YS; Er TK; Lu HC; Yeh KT; Chang JG
    Clin Chim Acta; 2014 Sep; 436():169-75. PubMed ID: 24863805
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas.
    Jancik S; Drabek J; Berkovcova J; Xu YZ; Stankova M; Klein J; Kolek V; Skarda J; Tichy T; Grygarkova I; Radzioch D; Hajduch M
    J Exp Clin Cancer Res; 2012 Sep; 31(1):79. PubMed ID: 22995035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Competitive amplification of differentially melting amplicons (CADMA) improves KRAS hotspot mutation testing in colorectal cancer.
    Kristensen LS; Kjeldsen TE; Hager H; Hansen LL
    BMC Cancer; 2012 Nov; 12():548. PubMed ID: 23173730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.
    Netzel BC; Grebe SK
    Clin Chim Acta; 2013 Oct; 425():1-2. PubMed ID: 23832066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
    Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
    Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of alterations in KRAS isoforms KRAS-4A/4B and KRAS mutations in colorectal carcinoma.
    Abubaker J; Bavi P; Al-Haqawi W; Sultana M; Al-Harbi S; Al-Sanea N; Abduljabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Uddin S; Al-Kuraya KS
    J Pathol; 2009 Dec; 219(4):435-45. PubMed ID: 19824059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology.
    Perez K; Walsh R; Brilliant K; Noble L; Yakirevich E; Breese V; Jackson C; Chatterjee D; Pricolo V; Roth L; Shah N; Cataldo T; Safran H; Hixson D; Quesenberry P
    Exp Mol Pathol; 2013 Aug; 95(1):74-82. PubMed ID: 23528430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial.
    Harbison CT; Horak CE; Ledeine JM; Mukhopadhyay P; Malone DP; O'Callaghan C; Jonker DJ; Karapetis CS; Khambata-Ford S; Gustafson N; Trifan OC; Chang SC; Ravetto P; Iv GA
    Arch Pathol Lab Med; 2013 Jun; 137(6):820-7. PubMed ID: 23030695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KRAS mutation testing in colorectal cancer: comparison of the results obtained using 3 different methods for the analysis of codons G12 and G13.
    Bihl MP; Hoeller S; Andreozzi MC; Foerster A; Rufle A; Tornillo L; Terracciano L
    Diagn Mol Pathol; 2012 Mar; 21(1):14-23. PubMed ID: 22306671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.